StreetAlpha.app
Home › Stocks › MNPR

Monopar Therapeutics (MNPR)

$69.00
▼ −1.84%
LAST CLOSE · NOV 20

Monopar Therapeutics develops pharmaceutical drug candidates for Wilson disease and radiopharmaceutical cancer treatment. It last closed at $69.00 on Nov 20, down 1.84% on the day. The next earnings report for MNPR is expected around Fri, Mar 26, 2027, after the close. For the quarter ended Sep 2026, MNPR reported EPS of -$0.72 on revenue of $0. Over its last 8 reports the stock moved an average of 4.9% the session after earnings. Over the last 12 months MNPR insiders bought $105K of stock on the open market and sold $4.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is MNPR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MNPR.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$20.6M
EPS (diluted)
−$2.44
Valuation
Market cap
$467.6M
6.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$52.6M
At Sep 30
Shareholder equity
$127.1M
Shares outstanding
6.8M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From MNPR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 26
Estimated date · After the close
Reported EPS
-$0.72
Quarter ended Sep 2026
Year ago EPS
-$0.48
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.75Dec '24Mar 2025: -$0.38Mar '25Jun 2025: -$0.35Jun '25Sep 2025: -$0.48Sep '25Dec 2025: -$0.64Dec '25Mar 2026: -$0.46Mar '26Jun 2026: -$0.62Jun '26Sep 2026: -$0.72Sep '26Latest -$0.72
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How MNPR moved after its last 8 reports
Average move the session after a report ±4.9%
Nov 12, 2026Time not announced+1.3%
Aug 12, 2026Time not announced+0.4%
May 14, 2026After the close−2.8%
Mar 27, 2026After the close−1.5%
Nov 13, 2025Time not announced+5.4%
Aug 12, 2025Time not announced+14.6%
May 13, 2025Time not announced−3.6%
Mar 31, 2025Time not announced−9.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MNPRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MNPR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MNPR

Technical Analysis

MNPR · as of the Nov 20 close · updated each morning
Downtrend

The stock is 3% below its 20 day and 14% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Oct 16) at $68.81, and the nearest resistance the Pivot R1 at $70.12.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.6%/day
Key levels
$124.8252 week high+80.9%
$94.74100 day average+37.3%
$78.3650 day average+13.6%
$77.49200 day average+12.3%
$75.08Swing high (Oct 21)+8.8%
$71.0320 day average+2.9%
$70.12Pivot R1+1.6%
$69.00Last close
$68.81Swing low (Oct 16)−0.3%
$68.74Pivot−0.4%
$67.62Pivot S1−2.0%
$50.0752 week low−27.4%
Indicators
RSI (14)39.88Weak, oversold below 30Neutral
MACD-2.15Above its signal lineBullish
Stochastic26.7Middle of its rangeNeutral
ADX (14)20.2Weak trend
Williams %R-83.3Oversold below −80, overbought above −20Oversold
CCI (20)-122.9Oversold below −100, overbought above 100Oversold
Rate of change−3.4%Change over 10 sessionsBearish
ATR (14)$4.58Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MNPR

What happened before

See how MNPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MNPR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MNPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MNPRHow many large options trades hit MNPR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MNPR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 38 selling
  • ●Held by funds -0.1 pts
  • ▲Funds holding +10
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10696+10.4%
In funds' top 1010–
Held by funds91.8%91.8%−0.1 pts
New / increased24 / 4028 / 32+6.7%
Reduced / sold out22 / 1624 / 140.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MNPR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MNPR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$105K1 buy · 1 insider
Sold$4.9M8 sales · 6 insiders
93% of the selling was under pre-arranged trading plans.
2025-12 bought $105K2025-12 sold $344K2026-08 sold $807K2026-09 sold $2.6M2026-10 sold $659K2026-11 sold $505KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 4Kim R TsuchimotoDirectorSale plan4,090$70.92$290K
Nov 2Raymond AndersonDirectorSale plan3,142$68.35$215K
Oct 1Christopher M StarrDirectorSale plan8,400$78.50$659K
Sep 24Chandler RobinsonCEOSale plan29,056$88.00$2.6M
Aug 26Kim R TsuchimotoDirectorSale plan4,090$111.39$456K
Aug 26Patrice RiouxActing Chief Medical OfficerSale plan1$111.26$111
Every insider buy and sale for MNPR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MNPR insider trades →

From SEC Form 4 filings by MNPR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNPR is in one of them and how their past MNPR trades turned out.

MNPR in the AI portfolios
Loading…

MNPR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNPR in an article yet. Here's the latest on the wider market.

MNPR in the news

About Monopar Therapeutics

Monopar Therapeutics is a pharmaceutical company based in Wilmette, Illinois, that develops drug candidates. Its candidates include ALXN1840, licensed from AstraZeneca and in development for Wilson disease, and MNPR-101, which is being developed for radiopharmaceutical use in cancer treatment. The company relies on patents and licensed intellectual property to protect these candidates.

Headquarters
Wilmette, IL